Holen Sie sich die Stockscreener-App
2.054
1.20%
-0.026
Schlusskurs vom Vortag:
$2.08
Offen:
$2.07
24-Stunden-Volumen:
138.07K
Relative Volume:
0.11
Marktkapitalisierung:
$129.68M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-1.30
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+3.79%
1M Leistung:
+20.88%
6M Leistung:
+2.75%
1J Leistung:
-13.66%
1-Tages-Spanne:
$2.01
$2.0886
1-Wochen-Bereich:
$1.81
$2.0886
52-Wochen-Spanne:
$0.9897
$2.485
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.05 | 131.58M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.26 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.25 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.28 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
Why is MacroGenics stock sinking Tuesday? - MSN
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold - Investing.com Nigeria
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
FDA Imposes Partial Clinical Hold on MacroGenics' (MGNX) Study - GuruFocus
Why Is MacroGenics Stock Sinking Tuesday? - Bitget
MacroGenics Pauses Enrollment Of Participants In LINNET Trial On FDA's Partial Clinical Hold - RTTNews
MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study - TipRanks
FDA halts new enrollment in MacroGenics (NASDAQ: MGNX) LINNET study - Stock Titan
Macrogenics announces pausing of enrollment of new study participants in Linnet trial - marketscreener.com
MacroGenics Faces Partial Clinical Hold from FDA on LINNET Study of Lorigerlimab in Gynecologic Cancers - Quiver Quantitative
FDA halts new enrollment in cancer trial after severe side effects - Stock Titan
Panic Selling: Will MacroGenics Inc outperform the market in YEAR2025 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Armistice Capital (MGNX) discloses 6.32M shares, 9.99% stake via Master Fund - Stock Titan
MacroGenics (NASDAQ: MGNX) SVP awarded RSUs, options and exercises units - Stock Titan
MacroGenics (MGNX) GC awarded 150,000 options and 25,000 RSUs - Stock Titan
Why MacroGenics Inc. stock is favored by pension fundsEarnings Beat & Accurate Entry/Exit Alerts - mfd.ru
Income Plays: Will MacroGenics Inc outperform the market in YEARPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
MGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Why MacroGenics Inc. stock remains a top recommendationJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Scott Koenig increases MacroGenics (MGNX) stake via 15,831 RSU conversion - Stock Titan
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Big Picture: Is Badger Meter Inc stock suitable for long term investing2025 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Retail Trends: What is the next catalyst for MacroGenics IncQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving AverageShould You Sell? - MarketBeat
Weekly Trades: Is MacroGenics Inc attractive for institutional investorsWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Will MacroGenics Inc outperform the market in YEAR2025 Biggest Moves & High Conviction Trade Alerts - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Is Via Renewables Inc impacted by rising ratesWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above 50 Day Moving Average – What’s Next? - Defense World
Meme Stocks: Is MacroGenics Inc attractive for institutional investorsLayoff News & Smart Money Movement Alerts - baoquankhu1.vn
Will MacroGenics Inc. stock benefit from green energy trendsJuly 2025 Sentiment & Consistent Income Trade Ideas - Улправда
How supply chain issues affect MacroGenics Inc. stockQuarterly Performance Summary & Weekly High Return Opportunities - Улправда
Market Leaders: How supply chain issues affect MacroGenics Inc. stockWeekly Investment Report & Step-by-Step Trade Execution Guides - ulpravda.ru
Will MacroGenics Inc. stock gain from government policiesEarnings Overview Summary & Risk Controlled Swing Alerts - Улправда
Exploring Sarah Faizy's Journey in Life Sciences Leadership - BioBuzz
How MacroGenics Inc. stock performs in rising dollar environment2026 world cup usa national team quarterfinals young talents pressing system odds analysis breakdown - ulpravda.ru
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):